Antifolate activators of AMP-dependent protein kinase
AMP 依赖性蛋白激酶的抗叶酸激活剂
基本信息
- 批准号:8037204
- 负责人:
- 金额:$ 29.09万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-03-02 至 2014-12-31
- 项目状态:已结题
- 来源:
- 关键词:5&apos-AMP-activated protein kinaseActive SitesAddressAffectAllelesAnabolismBindingBiochemical GeneticsCancer EtiologyCell LineCellsCellular biologyCharacteristicsCollectionColon CarcinomaDrug DesignDrug usageEffectivenessEmployee StrikesEnergy MetabolismEnzymatic BiochemistryEnzyme KineticsEnzymesEventFDA approvedFeedbackFolateFolic Acid AntagonistsGenesGeneticGenotypeGoalsGrowthHealthHumanHydroxymethyltransferasesHyperactive behaviorIn VitroKineticsLeadLearningLeukemic CellMalignant Epithelial CellMalignant NeoplasmsMesotheliomaMetabolicMetabolismMethodsModificationMolecular GeneticsMutationNon-Small-Cell Lung CarcinomaNuclearOncogene ActivationOncogenesPTEN genePathway interactionsPemetrexedPharmaceutical PreparationsProtein KinaseProtein Kinase InteractionProteinsProto-Oncogene Proteins c-aktPurine AntagonistPurinesPyrimidinesReactionRibonucleotidesRoleSTK11 geneSignal TransductionStructureTSC1/2 geneTherapeuticTherapeutic AgentsThymidylate SynthaseThymidylate Synthase InhibitorTumor Suppressor Genesanalogantitumor agentbasecancer cellconditioningcytotoxicitydesigndrug developmentfolic acid metabolismgenetic profilinghuman FRAP1 proteinin vivoinhibitor/antagonistlung CarcinomamTOR inhibitionneoplastic cellpolyglutamatespurineresearch studytooltumor
项目摘要
DESCRIPTION (provided by applicant): The majority of human cancers have lost the function of tumor suppressor genes (LKB1, PTEN, TSC1/2) controlling energy metabolism on the Akt-mTOR pathway or have hyperactivity of oncogenes (PI3kinase, Akt) on this same pathway. We have found that drugs that inhibit the second folate-dependent enzyme on the de novo purine biosynthesis pathway cause the accumulation of the substrate for that reaction, ZMP, and that this endogenously synthesized ZMP activates AMP-dependent protein kinase. Compounds that activate AMP kinase hava potential as antitumor agents since this enzyme acts as a key regulator of TORC1 on this pathway, restoring control in tumor cells with these genetic changes. This project proposes to study inhibitors of purine synthesis at the biochemical and molecular genetic levels to determine the mechanism of these effects and the utility of these inhibitors specifically to treat cancers that have genetic defects in the PI3kinase-mTOR pathway. The enzymology and cell biology of the lead compounds would be studied, and more potent inhibitors of the AICART formyltransferase reaction would be designed as targeted therapeutic agents
PUBLIC HEALTH RELEVANCE: The majorities of human cancers have lost the function of tumor suppressor genes controlling energy metabolism on the Akt-mTOR pathway or have hyperactivity of cancer-causing genes on this pathway. We have found that drugs that inhibit a folate- dependent enzyme on the purine biosynthesis pathway cause the accumulation of a metabolite, ZMP, that can reactivate the AMP-dependent protein kinase that regulates this pathway, restoring control in tumor cells with these genetic changes. This project proposes to study this effect at the biochemical and molecular genetic levels and to develop potent inhibitors of this folate-dependent enzyme.
描述(申请人提供):大多数人类癌症都失去了控制Akt-mTOR途径能量代谢的肿瘤抑制基因(LKB 1、PTEN、TSC 1/2)的功能,或者在同一途径上具有癌基因(PI 3激酶、Akt)的过度活性。我们已经发现,抑制嘌呤生物合成途径上的第二种叶酸依赖性酶的药物导致该反应的底物ZMP的积累,并且这种内源性合成的ZMP激活AMP依赖性蛋白激酶。激活AMP激酶的化合物具有作为抗肿瘤剂的潜力,因为这种酶在该途径上充当TORC 1的关键调节剂,通过这些遗传变化恢复对肿瘤细胞的控制。本项目拟在生物化学和分子遗传学水平上研究嘌呤合成抑制剂,以确定这些作用的机制以及这些抑制剂专门用于治疗PI 3激酶-mTOR通路中存在遗传缺陷的癌症的效用。先导化合物的酶学和细胞生物学将被研究,并且更有效的AICART甲酰转移酶反应抑制剂将被设计为靶向治疗剂
公共卫生关系:大多数人类癌症已经失去了控制Akt-mTOR途径上能量代谢的肿瘤抑制基因的功能,或者在该途径上具有致癌基因的过度活性。我们已经发现,抑制嘌呤生物合成途径上的叶酸依赖性酶的药物引起代谢物ZMP的积累,ZMP可以重新激活调节该途径的AMP依赖性蛋白激酶,恢复对具有这些遗传变化的肿瘤细胞的控制。该项目建议在生物化学和分子遗传水平上研究这种效应,并开发这种叶酸依赖性酶的有效抑制剂。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RICHARD G MORAN其他文献
RICHARD G MORAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RICHARD G MORAN', 18)}}的其他基金
Antifolate activators of AMP-dependent protein kinase
AMP 依赖性蛋白激酶的抗叶酸激活剂
- 批准号:
8403807 - 财政年份:2010
- 资助金额:
$ 29.09万 - 项目类别:
Antifolate activators of AMP-dependent protein kinase
AMP 依赖性蛋白激酶的抗叶酸激活剂
- 批准号:
7889262 - 财政年份:2010
- 资助金额:
$ 29.09万 - 项目类别:
Antifolate activators of AMP-dependent protein kinase
AMP 依赖性蛋白激酶的抗叶酸激活剂
- 批准号:
8601175 - 财政年份:2010
- 资助金额:
$ 29.09万 - 项目类别:
Antifolate activators of AMP-dependent protein kinase
AMP 依赖性蛋白激酶的抗叶酸激活剂
- 批准号:
8208107 - 财政年份:2010
- 资助金额:
$ 29.09万 - 项目类别:
HUMAN MITOCHONDRIAL FOLATE/ANTIFOLATE TRANSPORT
人体线粒体叶酸/抗叶酸转运
- 批准号:
6706016 - 财政年份:2004
- 资助金额:
$ 29.09万 - 项目类别:
HUMAN MITOCHONDRIAL FOLATE/ANTIFOLATE TRANSPORT
人体线粒体叶酸/抗叶酸转运
- 批准号:
7218711 - 财政年份:2004
- 资助金额:
$ 29.09万 - 项目类别:
HUMAN MITOCHONDRIAL FOLATE/ANTIFOLATE TRANSPORT
人体线粒体叶酸/抗叶酸转运
- 批准号:
6880103 - 财政年份:2004
- 资助金额:
$ 29.09万 - 项目类别:
HUMAN MITOCHONDRIAL FOLATE/ANTIFOLATE TRANSPORT
人体线粒体叶酸/抗叶酸转运
- 批准号:
7038320 - 财政年份:2004
- 资助金额:
$ 29.09万 - 项目类别:
HUMAN MITOCHONDRIAL FOLATE/ANTIFOLATE TRANSPORT
人体线粒体叶酸/抗叶酸转运
- 批准号:
7367915 - 财政年份:2004
- 资助金额:
$ 29.09万 - 项目类别:
ANTIFOLATES INHIBITORY TO FOLYLPOLYGLUTAMATE SYNTHETASE
抑制叶酰聚谷氨酸合成酶的抗叶酸剂
- 批准号:
3179005 - 财政年份:1985
- 资助金额:
$ 29.09万 - 项目类别:
相似海外基金
Pharmacological targeting of AMP-activated protein kinase for immune cell regulation in Type 1 Diabetes
AMP 激活蛋白激酶对 1 型糖尿病免疫细胞调节的药理学靶向
- 批准号:
2867610 - 财政年份:2023
- 资助金额:
$ 29.09万 - 项目类别:
Studentship
Establishing AMP-activated protein kinase as a regulator of adipose stem cell plasticity and function in health and disease
建立 AMP 激活蛋白激酶作为脂肪干细胞可塑性和健康和疾病功能的调节剂
- 批准号:
BB/W009633/1 - 财政年份:2022
- 资助金额:
$ 29.09万 - 项目类别:
Fellowship
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
- 批准号:
532989-2019 - 财政年份:2021
- 资助金额:
$ 29.09万 - 项目类别:
Postdoctoral Fellowships
Metabolic control of integrin membrane traffic by AMP-activated protein kinase controls cell migration.
AMP 激活的蛋白激酶对整合素膜运输的代谢控制控制着细胞迁移。
- 批准号:
459043 - 财政年份:2021
- 资助金额:
$ 29.09万 - 项目类别:
Studentship Programs
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
- 批准号:
532989-2019 - 财政年份:2020
- 资助金额:
$ 29.09万 - 项目类别:
Postdoctoral Fellowships
The Role of AMP-activated Protein Kinase in GVHD-causing T Cells
AMP 激活的蛋白激酶在引起 GVHD 的 T 细胞中的作用
- 批准号:
10561642 - 财政年份:2019
- 资助金额:
$ 29.09万 - 项目类别:
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
- 批准号:
532989-2019 - 财政年份:2019
- 资助金额:
$ 29.09万 - 项目类别:
Postdoctoral Fellowships
Treating Diabetic Inflammation using AMP-Activated Protein Kinase Activators
使用 AMP 激活的蛋白激酶激活剂治疗糖尿病炎症
- 批准号:
2243045 - 财政年份:2019
- 资助金额:
$ 29.09万 - 项目类别:
Studentship
The Role of AMP-activated Protein Kinase in GVHD-causing T Cells
AMP 激活的蛋白激酶在引起 GVHD 的 T 细胞中的作用
- 批准号:
10359032 - 财政年份:2019
- 资助金额:
$ 29.09万 - 项目类别:
Investigating the therapeutic potential of AMP-activated protein kinase in myotonic dystrophy type 1
研究 AMP 激活蛋白激酶在 1 型强直性肌营养不良中的治疗潜力
- 批准号:
428988 - 财政年份:2019
- 资助金额:
$ 29.09万 - 项目类别:
Studentship Programs